Seven Fleet Capital Management LP Has $7.46 Million Position in Vaxcyte, Inc. $PCVX

Seven Fleet Capital Management LP boosted its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 406.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 128,450 shares of the company’s stock after buying an additional 103,085 shares during the quarter. Vaxcyte accounts for about 2.3% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 10th largest position. Seven Fleet Capital Management LP’s holdings in Vaxcyte were worth $7,464,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of PCVX. Smartleaf Asset Management LLC increased its holdings in shares of Vaxcyte by 156.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after buying an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Vaxcyte by 1,463.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after acquiring an additional 600 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Vaxcyte by 33.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after acquiring an additional 184 shares in the last quarter. CIBC Private Wealth Group LLC grew its holdings in shares of Vaxcyte by 22,500.0% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock worth $49,000 after acquiring an additional 1,350 shares during the last quarter. Finally, Capital Advisors Ltd. LLC acquired a new position in shares of Vaxcyte in the 1st quarter worth $58,000. Institutional investors own 96.78% of the company’s stock.

Analyst Upgrades and Downgrades

PCVX has been the topic of a number of recent analyst reports. Wall Street Zen lowered Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Finally, Zacks Research cut Vaxcyte from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $86.00.

Insider Buying and Selling

In related news, CFO Andrew Guggenhime sold 10,000 shares of the stock in a transaction on Monday, July 6th. The stock was sold at an average price of $57.28, for a total transaction of $572,800.00. Following the completion of the sale, the chief financial officer directly owned 104,395 shares in the company, valued at approximately $5,979,745.60. This trade represents a 8.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Grant Pickering sold 2,000 shares of Vaxcyte stock in a transaction on Monday, July 27th. The shares were sold at an average price of $55.65, for a total value of $111,300.00. Following the sale, the chief executive officer directly owned 133,215 shares of the company’s stock, valued at approximately $7,413,414.75. The trade was a 1.48% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 91,396 shares of company stock worth $4,975,725. Corporate insiders own 3.30% of the company’s stock.

Vaxcyte Stock Performance

Vaxcyte stock opened at $54.08 on Friday. Vaxcyte, Inc. has a twelve month low of $29.08 and a twelve month high of $65.00. The firm has a market cap of $7.81 billion, a PE ratio of -7.86 and a beta of 1.22. The firm’s 50 day moving average price is $53.25 and its two-hundred day moving average price is $54.89.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same quarter in the prior year, the business earned ($1.04) EPS. Equities analysts anticipate that Vaxcyte, Inc. will post -7.91 EPS for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.